{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T08:45:01Z","timestamp":1792053901530,"version":"4.4.0"},"reference-count":28,"publisher":"Wiley","issue":"20","license":[{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"vor","delay-in-days":14,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Thoracic Cancer"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    Trilaciclib, a cyclin\u2010dependent kinase 4 and 6 (CDK4\/6) inhibitor administered before chemotherapy, reduces chemotherapy\u2010induced myelosuppression (CIM) in extensive\u2010stage small cell lung cancer (ES\u2010SCLC), but its efficacy across solid tumors remains unclear. This meta\u2010analysis evaluated the efficacy and safety of trilaciclib in solid tumor patients receiving chemotherapy. PubMed, Embase, Cochrane Library, and\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/clinicaltrials.gov\">ClinicalTrials.gov<\/jats:ext-link>\n                    were searched from inception to January 21, 2026. Randomized controlled trials (RCTs) and cohort studies comparing chemotherapy with or without trilaciclib were included. Primary outcomes were severe neutropenia (SN), febrile neutropenia (FN), duration of severe neutropenia (DSN), Grade 3\/4 leukopenia, and granulocyte colony\u2010stimulating factor (G\u2010CSF) use. Secondary outcomes included other hematologic toxicities, supportive care interventions, and efficacy outcomes. Ten studies involving 1172 patients (six RCTs and four cohort studies) were identified. Trilaciclib significantly reduced SN (OR, 0.14; 95% CI, 0.06\u20130.31;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001), FN (OR, 0.19; 95% CI, 0.11\u20130.36;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001), Grade 3\/4 leukopenia (OR, 0.25; 95% CI, 0.13\u20130.46;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001), and G\u2010CSF use (OR, 0.36; 95% CI, 0.18\u20130.71;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.0087), and shortened DSN (MD, \u22122.30\u2009days; 95% CI, \u22124.28 to \u22120.31;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.0309). It also reduced Grade 3\/4 anemia and thrombocytopenia and decreased use of erythropoiesis\u2010stimulating agents, red blood cell transfusions, and platelet transfusions. Overall survival showed a borderline improvement (HR, 0.84; 95% CI, 0.71\u20130.99;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.0373), while no significant differences were observed in progression\u2010free survival, overall response rate, or non\u2010hematologic adverse events. Subgroup analyses suggested greater benefit in ES\u2010SCLC. Overall, trilaciclib before chemotherapy significantly reduced CIM and supportive care needs, with no apparent compromise in antitumor efficacy and more pronounced effects in ES\u2010SCLC.\n                  <\/jats:p>","DOI":"10.1111\/1759-7714.70402","type":"journal-article","created":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T07:58:17Z","timestamp":1792051097000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Safety of Trilaciclib for the Prevention of Chemotherapy\u2010Induced Myelosuppression in Patients With Solid Tumors: A Systematic Review and Meta\u2010Analysis"],"prefix":"10.1111","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-5377-2927","authenticated-orcid":false,"given":"Wei","family":"Tian","sequence":"first","affiliation":[{"name":"Department of Pharmacy Peking University First Hospital  Beijing China"},{"name":"School of Traditional Chinese Medicine Tianjin University of Traditional Chinese Medicine  Tianjin China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3722-403X","authenticated-orcid":false,"given":"Qianxin","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Peking University First Hospital  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2562-8323","authenticated-orcid":false,"given":"Ying","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Peking University First Hospital  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3619-9408","authenticated-orcid":false,"given":"Zhuo","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Peking University First Hospital  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,10,15]]},"reference":[{"issue":"3","key":"e_1_2_12_2_1","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1001\/jamaoncol.2022.5631","article-title":"Emerging Strategies for the Treatment of Small Cell Lung Cancer: A Review","volume":"9","author":"Petty W. J.","year":"2023","journal-title":"JAMA Oncology"},{"issue":"2","key":"e_1_2_12_3_1","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41571-021-00565-2","article-title":"Treatment Landscape of Triple\u2010Negative Breast Cancer \u2010 Expanded Options, Evolving Needs","volume":"19","author":"Bianchini G.","year":"2022","journal-title":"Nature Reviews. Clinical Oncology"},{"issue":"11","key":"e_1_2_12_4_1","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15112620","article-title":"Colorectal Cancer: Disease Process, Current Treatment Options, and Future Perspectives","volume":"15","author":"Adebayo A. S.","year":"2023","journal-title":"Pharmaceutics"},{"issue":"4","key":"e_1_2_12_5_1","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1002\/ijc.29045","article-title":"Hematologic Toxicity Assessment in Solid Tumor Patients Treated With Cetuximab: A Pooled Analysis of 18 Randomized Controlled Trials","volume":"136","author":"Cui R.","year":"2015","journal-title":"International Journal of Cancer"},{"issue":"21","key":"e_1_2_12_6_1","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.2217\/fon-2023-0513","article-title":"The Impact of Myelosuppression on Quality of Life of Patients Treated With Chemotherapy","volume":"20","author":"Crawford J.","year":"2024","journal-title":"Future Oncology"},{"issue":"8","key":"e_1_2_12_7_1","doi-asserted-by":"crossref","first-page":"3606","DOI":"10.1007\/s12325-020-01419-6","article-title":"Patient Burden and Real\u2010World Management of Chemotherapy\u2010Induced Myelosuppression: Results From an Online Survey of Patients With Solid Tumors","volume":"37","author":"Epstein R. S.","year":"2020","journal-title":"Advances in Therapy"},{"issue":"7","key":"e_1_2_12_8_1","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s40265-021-01508-y","article-title":"Trilaciclib: First Approval","volume":"81","author":"Dhillon S.","year":"2021","journal-title":"Drugs"},{"issue":"387","key":"e_1_2_12_9_1","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aal3986","article-title":"Transient CDK4\/6 Inhibition Protects Hematopoietic Stem Cells From Chemotherapy\u2010Induced Exhaustion","volume":"9","author":"He S.","year":"2017","journal-title":"Science Translational Medicine"},{"issue":"10","key":"e_1_2_12_10_1","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1093\/annonc\/mdz278","article-title":"Myelopreservation With the CDK4\/6 Inhibitor Trilaciclib in Patients With Small\u2010Cell Lung Cancer Receiving First\u2010Line Chemotherapy: A Phase Ib\/Randomized Phase II Trial","volume":"30","author":"Weiss J. M.","year":"2019","journal-title":"Annals of Oncology"},{"issue":"1","key":"e_1_2_12_11_1","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1007\/s12325-020-01538-0","article-title":"Myelopreservation With Trilaciclib in Patients Receiving Topotecan for Small Cell Lung Cancer: Results From a Randomized, Double\u2010Blind, Placebo\u2010Controlled Phase II Study","volume":"38","author":"Hart L. L.","year":"2021","journal-title":"Advances in Therapy"},{"key":"e_1_2_12_12_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2023.107455","article-title":"Myeloprotection With Trilaciclib in Chinese Patients With Extensive\u2010Stage Small Cell Lung Cancer Receiving Chemotherapy: Results From a Randomized, Double\u2010Blind, Placebo\u2010Controlled Phase III Study (TRACES)","volume":"188","author":"Cheng Y.","year":"2024","journal-title":"Lung Cancer"},{"issue":"1","key":"e_1_2_12_13_1","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pkae116","article-title":"Trilaciclib Prior to FOLFOXIRI\/Bevacizumab for Patients With Untreated Metastatic Colorectal Cancer: Phase 3 Preserve 1 Trial","volume":"9","author":"Lenz H. J.","year":"2025","journal-title":"JNCI Cancer Spectrum"},{"issue":"11","key":"e_1_2_12_14_1","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/S1470-2045(19)30616-3","article-title":"Trilaciclib Plus Chemotherapy Versus Chemotherapy Alone in Patients With Metastatic Triple\u2010Negative Breast Cancer: A Multicentre, Randomised, Open\u2010Label, Phase 2 Trial","volume":"20","author":"Tan A. R.","year":"2019","journal-title":"Lancet Oncology"},{"key":"e_1_2_12_15_1","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1157251","article-title":"The Efficacy and Safety of Trilaciclib in Preventing Chemotherapy\u2010Induced Myelosuppression: A Systematic Review and Meta\u2010Analysis of Randomized Controlled Trials","volume":"14","author":"Qiu J.","year":"2023","journal-title":"Frontiers in Pharmacology"},{"key":"e_1_2_12_16_1","doi-asserted-by":"crossref","DOI":"10.1002\/9781119536604","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins J. P. T.","year":"2019"},{"key":"e_1_2_12_17_1","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 Statement: An Updated Guideline for Reporting Systematic Reviews","volume":"372","author":"Page M. J.","year":"2021","journal-title":"BMJ"},{"key":"e_1_2_12_18_1","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: A Revised Tool for Assessing Risk of Bias in Randomised Trials","volume":"366","author":"Sterne J. A. C.","year":"2019","journal-title":"BMJ"},{"issue":"9","key":"e_1_2_12_19_1","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","article-title":"Methodological Index for Non\u2010Randomized Studies (MINORS): Development and Validation of a New Instrument","volume":"73","author":"Slim K.","year":"2003","journal-title":"ANZ Journal of Surgery"},{"issue":"10","key":"e_1_2_12_20_1","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1002\/ijc.33453","article-title":"Trilaciclib Prior to Chemotherapy and Atezolizumab in Patients With Newly Diagnosed Extensive\u2010Stage Small Cell Lung Cancer: A Multicentre, Randomised, Double\u2010Blind, Placebo\u2010Controlled Phase II Trial","volume":"148","author":"Daniel D.","year":"2021","journal-title":"International Journal of Cancer"},{"issue":"9","key":"e_1_2_12_21_1","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1007\/s00520-024-08828-1","article-title":"Trilaciclib Use in Extensive\u2010Stage Small Cell Lung Cancer (ES\u2010SCLC): Are Clinical Benefits Seen in the Real\u2010World Setting?","volume":"32","author":"Elijah J.","year":"2024","journal-title":"Supportive Care in Cancer"},{"issue":"8","key":"e_1_2_12_22_1","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.70862","article-title":"Real\u2010World Assessment of Trilaciclib for the Prevention of Chemoradiotherapy\u2010Induced Myelosuppression in Esophageal Squamous Cell Carcinoma: A Propensity Score Matching Study","volume":"14","author":"Yan J.","year":"2025","journal-title":"Cancer Medicine"},{"issue":"13","key":"e_1_2_12_23_1","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1080\/1750743X.2025.2559578","article-title":"The Value and Safety of Trilaciclib in Combination With First\u2010Line Chemotherapy and Immunotherapy for Extensive\u2010Stage SCLC","volume":"17","author":"He S.","year":"2025","journal-title":"Immunotherapy"},{"issue":"6","key":"e_1_2_12_24_1","first-page":"564","article-title":"Application Value and Safety of Trilaciclib in First\u2010Line Chemotherapy Combined With Immunotherapy for Extensive\u2010Stage Small Cell Lung Cancer: A Real\u2010World Study","volume":"30","author":"Cui Y.","year":"2025","journal-title":"Oncology Letters"},{"issue":"2","key":"e_1_2_12_25_1","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000847","article-title":"CDK4\/6 Inhibition Enhances Antitumor Efficacy of Chemotherapy and Immune Checkpoint Inhibitor Combinations in Preclinical Models and Enhances T\u2010Cell Activation in Patients With SCLC Receiving Chemotherapy","volume":"8","author":"Lai A. Y.","year":"2020","journal-title":"Journal for Immunotherapy of Cancer"},{"issue":"2","key":"e_1_2_12_26_1","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s10549-023-07009-8","article-title":"Investigating Potential Immune Mechanisms of Trilaciclib Administered Prior to Chemotherapy in Patients With Metastatic Triple\u2010Negative Breast Cancer","volume":"201","author":"Tan A. R.","year":"2023","journal-title":"Breast Cancer Research and Treatment"},{"issue":"8","key":"e_1_2_12_27_1","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/oncolo\/oyac074","article-title":"Chemotherapy\u2010Induced Neutropenia and Febrile Neutropenia in the US: A Beast of Burden That Needs To be Tamed?","volume":"27","author":"Boccia R.","year":"2022","journal-title":"Oncologist"},{"issue":"16","key":"e_1_2_12_28_1","article-title":"The Potential Benefits of Trilaciclib on Blood Product Utilization and Neutropenic Fever Episodes in Small Cell Lung Cancer Patients: A Propensity\u2010Matched Cohort Study","volume":"43","author":"Oza Q.","year":"2025","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"e_1_2_12_29_1","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1200\/JCO.21.01881","article-title":"Extensive\u2010Stage Small\u2010Cell Lung Cancer: First\u2010Line and Second\u2010Line Treatment Options","volume":"40","author":"Zugazagoitia J.","year":"2022","journal-title":"Journal of Clinical Oncology"}],"container-title":["Thoracic Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1759-7714.70402","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/1759-7714.70402","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1759-7714.70402","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T07:58:21Z","timestamp":1792051101000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1759-7714.70402"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":28,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1111\/1759-7714.70402"],"URL":"https:\/\/doi.org\/10.1111\/1759-7714.70402","archive":["Portico"],"relation":{},"ISSN":["1759-7706","1759-7714"],"issn-type":[{"value":"1759-7706","type":"print"},{"value":"1759-7714","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"2026-04-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70402"}}